The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model
Summary
Demonstrated that ARA-290 prevented the development of mechanical allodynia (neuropathic pain) in a nerve inflammation model. Both low and high doses were equally effective, suggesting potential for treating neuropathic pain where nerve injury is absent on clinical assessment.
Key Findings
- ARA-290 prevented development of mechanical allodynia in neuritis model
- Both 30 and 120 mcg/kg doses were equally effective
- Suggests therapeutic potential for neuropathic pain from nerve inflammation without frank injury
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Related Studies
View all →Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the beta-common receptor in mice with cerebral ischemic stroke
Wang RL, Yang ZH, Huang YY, et al.
CNS Neuroscience & Therapeutics
Showed that ARA-290 exerts neuroprotective effects comparable to erythropoietin in a mouse middle cerebral artery occlusion model, without causing erythropoiesis. The protective mechanism operates through the beta-common receptor, reducing neuronal apoptosis and inflammatory cytokines.
- ARA-290 provided neuroprotection comparable to EPO in cerebral ischemic stroke model
- Neuroprotective effect mediated specifically through the beta-common receptor
DOI: 10.1111/cns.14688
Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection
Liu Y, Luo B, Han F, et al.
PLoS ONE
Demonstrated that ARA-290, an EPO-derived nonerythropoietic peptide, significantly improved recovery in experimental autoimmune neuritis without inducing erythropoiesis. The peptide suppressed inflammation, promoted nerve regeneration and remyelination, and modulated T cell differentiation.
- ARA-290 improved nerve regeneration and remyelination without stimulating erythropoiesis
- Increased regulatory T cells and Th2 cells while decreasing Th1 cells